NORD gratefully acknowledges Maria A. Woodward, MD, Assistant Professor of Ophthalmology, University of Michigan, for assistance in the preparation of this report.
The corneas in both eyes are usually affected (bilateral), although the progression and severity of the condition in each eye may differ (asymmetric development), which means one eye may be notably worse than the other. Symptoms usually become apparent during adolescence or young adulthood (i.e. late teens through early 20s). Keratoconus may become progressively worse for 10 to 20 years before slowing. Older adults typically do not have worsening of keratoconus. Because of the progressive nature of the disorder, affected individuals may have to change glasses frequently.
The cornea has two main functions: protecting the rest of the eye from dust, germs and other harmful or irritating material, and acting as the eye’s outermost lens, bending incoming light onto the inner lens, where the light is then directed to the retina (a membranous layer of light-sensing cells in the back of the eye). The retina converts light to specific nerve signals, which are then transmitted to the brain to form images. The cornea must remain clear (transparent) and the proper shape in order to be able to focus incoming light.
The abnormal cone-shape that characterizes keratoconus leads to changes in the ability of the cornea to help focus light appropriately on the retina (i.e., refractive abnormalities). Keratoconus may initially cause slight blurring of vision, abnormally increased sensitivity to glare or bright light, and difficulty seeing at night (poor night vision). Some individuals may experience double vision (diplopia) or see multiple images or a partial, incomplete image around what they are looking at (‘ghost’ images). In some cases, there may be a sudden loss of clarity of vision (visual acuity). With progressive corneal changes, affected individuals experience increased difficulty in seeing far away (nearsightedness or myopia) and further decreased clarity of vision. Overall vision changes can vary from one person to another and the severity can range from mild vision loss to more severe vision loss that causes a decreased ability to see clearly even with corrective lenses. Some affected individuals may develop an irregular astigmatism, in which there is an irregular curvature of the eye.
In rare cases, affected individuals may develop a corneal blister that causes swelling of the cornea due to fluid accumulation (acute corneal hydrops) in specific layers of the cornea. This condition can be painful and cause redness of the eye. Scarring of the cornea can occur.
The specific underlying mechanism(s) responsible for keratoconus are not fully understood. Most cases appear to occur randomly for unknown reasons (sporadically). However, a positive family history of keratoconus has been established in some cases. Most researchers believe that multiple, complex factors are required for the development of keratoconus including both genetic and environmental factors.
Researchers believe that some individuals who develop keratoconus have a genetic predisposition to developing the disorder. A person who is genetically predisposed to a disorder carries a gene (or genes) for the disorder, but the condition may not be expressed unless it is triggered or “activated” under certain circumstances such as due to particular environmental factors. Research is underway to identify specific genes associated with keratoconus.
Environmental risk factors that may play a role in the development of keratoconus include contact lens use, repeated eye-rubbing, or atophy, a general term for conditions that are hypersensitive or ‘hyper-allergic such as hay fever (allergic rhinitis), eczema (atopic dermatitis), sleep apnea, or allergic asthma. However, studies have proven an association with any of these potential risk factors and the development of keratoconus.
Traditionally, keratoconus has been considered a non-inflammatory disorder. Inflammation is a normal process that occurs in the body in response to injury or infection. In inflammatory disorders there is an abnormal immune (inflammatory) response, which can lead to symptoms or specific disorders. Although keratoconus has been defined as a non-inflammatory disorder recent evidence including abnormally high levels of proteolytic enzymes, an association with free radicals and oxidative stress, or the presence of cytokines, specialized proteins secreted from certain immune system cells that either stimulate or inhibit the function of other immune system cells. More research is necessary to determine the complex, underlying causes of keratoconus.
Keratoconus may also sometimes occur in association with certain underlying disorders, such as Down syndrome, sleep apnea, asthma, Leber congenital amaurosis, and various connective tissue disorders including Ehlers-Danlos syndrome, Marfan syndrome, or brittle cornea syndrome. A direct cause-and-effect relationship between these disorders and keratoconus has not been established. (For additional information on these disorders, please choose the appropriate name as your search term in the Rare Disease Database or see the “Related Disorders” section of this report below.)
Keratoconus affects both men and women and all ethnic groups worldwide. The disorder tends to develop most often among adolescents at or around puberty or during the late teen-age years. Recent studies (2015) show that men, African-Americans, and Latinos have a greater risk of development keratoconus, while women, Asian-Americans, and people with diabetes appear to have a lower risk.
The incidence and prevalence rates reported in the medical literature for keratoconus tend to vary widely. One long-term study in the United States indicated a prevalence rate of 54.5 diagnosed individuals per 100,000 individuals in the general population, or approximately 1 in 2,000 individuals. However, some estimates suggest that the incidence may be as high as 1 in 400 individuals. Individuals with a family history of keratoconus are at a greater risk of developing the condition than people the general population.
Keratoconus may be diagnosed based upon a complete patient and family history and thorough eye examination. Such an examination may include evaluation of the external appearance of the eyes, visual acuity, eye movements, and visual fields; the use of a special, illuminated microscope that allows physicians to view the eye through high magnification (slit-lamp examination); and/or additional tests or procedures.
A specific imaging tests known as corneal topography is used to aid in a diagnosis of keratoconus, in part by detecting very early keratoconus where the corneal changes are not visible by a doctor looking at the eye (subclinical). This is sometimes referred to as “forme fruste” keratoconus. Corneal topography is an imaging study that uses an instrument to project a series of light rings onto the surface of the cornea. These rings of light are reflected back to the instrument and recorded. These recording can show changes in the shape and integrity of the cornea. Corneal topography is useful for determining the severity of keratoconus and monitoring the progression of the disorder.
The treatment of keratoconus is based upon the severity of the condition in the individual and the rate of progression of the disorder. In some individuals with mild symptoms, vision may be improved with the use of appropriate eyeglasses or soft contact lenses. However, progressive changes in vision often necessitate frequent prescription changes.
In many individuals, rigid gas permeable contact lenses (a modern version of ‘hard’ contact lenses) may be required. These lenses can reshape the corneal surface to hide or mask the underlying cone-shaped defect of the cornea. In some individuals, these contact lenses may become uncomfortable and are not tolerated well. In such cases, individuals can use ‘piggyback’ contacts lenses in which hard contact lenses are placed over soft lenses. The underlying soft lenses provide comfort and support, while the hard lenses improves vision. Other types of contact lenses that may be used include hybrid lenses, which have a rigid center and soft ring on the outside, or scleral lenses, which are larger traditional contact lenses and which rest atop the sclera (the whites of the eyes) and mount above the cornea.
However, some severely affected individuals may not be able to wear contact lenses due to progressively severe corneal thinning, corneal scarring, and/or contact intolerance. In cases of severe visual deterioration in which contact lenses cannot sufficiently correct vision or are not tolerated, surgery may be required such as intracorneal ring segments or a corneal transplant (keratoplasty).
In July of 2004, the U.S. Food and Drug Administration approved intracorneal ring segments for the treatment of individuals with keratoconus. During this procedure, two, tiny crescent-shaped plastic pieces are inserted into the cornea. These inserts can help to flatten, strengthen, and support the cornea and improve vision. Typically, eyeglasses or contact lenses are still required for proper vision.
In 2016, Photrexa was approved to treat progressive keratoconus with corneal collagen crosslinking. This is the first FDA approved treatment for this condition, and is manufactured by Avedro, Inc.
A corneal transplant is a surgical procedure in which abnormal corneal tissue is removed and replaced with healthy donor corneal tissue. This surgery is generally reserved for individuals with severe disease (e.g. the cornea is extremely thin and/or vision is significantly compromised) or who cannot tolerate or did not respond to more conservative treatments. A corneal transplant may also be indicated for acute corneal fluid (corneal hydrops) that did not respond to other treatment options. There are several different corneal transplant procedures that may be used. Corneal transplant are generally effective for treating individuals with keratoconus, but do carry a small risk of complications including rejection of the donated tissue by the body (graft rejection). Of note, individuals who have a corneal transplant typically still need hard contact lenses after the transplant because the cornea, while flatter, still does not have a perfect shape.
A procedure known as corneal collagen cross-linking (CXL) has been used to successfully treat individuals with keratoconus. This procedure has yet to be approved by the FDA for the treatment of individuals with keratoconus but is used worldwide with excellent clinical evidence to support the effectiveness of the procedure. This procedure uses ultraviolet A (UVA) light and riboflavin, a type of B vitamin, to slow or halt the progression of keratoconus. During the procedure, riboflavin is placed on the cornea via eye drops. Riboflavin acts as a photosensitizer, which allows corneal tissue to absorb the ultraviolet light. Basically, this procedure creates new bonds in the collagen of the cornea, strengthening the cornea and halting progression. In some cases, the cornea obtains a flatter shape after CXL, but it does not return to ‘normal’ entirely.
A procedure known as topography-guided photorefractive keratectomy has been combined with collagen cross-linking to treat some individuals with mild to moderate keratoconus. Photorefractive keratectomy is a type of laser eye surgery that is most often used to treat individuals with mild or moderate nearsightedness, farsightedness or astigmatism. Generally, laser surgery is not recommended (contraindicated) for individuals with keratoconus. During this procedure a laser is used to reshape the affected cornea(s). More research is necessary to determine the long-term safety and effectiveness of this potential procedure for specific individuals with keratoconus.
Researchers are also studying the effectiveness of combining investigational therapies such as collagen crosslinking combined with intracorneal ring inserts.
Information on current clinical trials is posted on the Internet at www.clinicaltrials.gov. All studies receiving U.S. government funding, and some supported by private industry, are posted on this government web site.
For information about clinical trials being conducted at the NIH Clinical Center in Bethesda, MD, contact the NIH Patient Recruitment Office:
Toll-free: (800) 411-1222
TTY: (866) 411-1010
For information about clinical trials sponsored by private sources, contact:
Rabinowitz YS. Ectatic Diseases of the Cornea. In: Smolin and Thoft’s The Cornea: Scientific Foundations & Clinical Practice, 4th ed. Foster CS, Azar DT, Dohlman CH, editors. 2005 Lippincott, Williams & Wilkins, Philadelphia, PA. pp. 889-913.
Wicker D, Farjo AA, Taylor B, Gromacki S. Keratoconus. In: NORD Guide to Rare Disorders. Lippincott Williams & Wilkins. Philadelphia, PA. 2003:650-651.
Woodward MA, Blachley TS, Stein JD. The association between sociodemographic factors, common systemic diseases, and keratoconus: an analysis of a nationwide health care claims database. Ophthalmology. 2015;[Epub ahead of print]. http://www.ncbi.nlm.nih.gov/pubmed/26707415
Gordon-Shaag A, Millodot M, Shneor E, Liu Y. The genetic and environmental factors for keatoconus. Biomed Res Int. 2015;2015:795738. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4449900/
Galvis V, Sherwin T, Tello A, et al. Keratoconus: an inflammatory disorder? Eye (Lond). 2015;29:843-859. http://www.ncbi.nlm.nih.gov/pubmed/25931166
Sandeep Tambe D, Ivarsen A, Hjortdal J. Photorefractive keratectomy in keratoconus. Case Rep Ophthalmol. 2015;6:260-268. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4553919/
Li J, Ji P, Lin X. Efficacy of corneal collagen cross-linking for treatment of keratoconus: a meta-analysis of randomized controlled trials. PLoS. 2015;10:e0127079. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4436191/
Abu-Amero KK, Al-Muammar AM, Kondkar AA. Genetics of keratoconus: where do we stand? J Ophthalmol. 2014;2014:641708. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4164130/
Davidson AE, Hayes S, Hardcastle AJ, Tuft SJ. The pathogenesis of keratoconus. Eye (Lond). 2014;28:189-195. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3930280/
Sorkin N, Varsanno D. Corneal collagen crosslinking: a systemic review. Ophthalmologica. 2014;232:10-27. http://www.ncbi.nlm.nih.gov/pubmed/24751584
Fan Gaskin JC, Patel DV, McGhee CN. Acute corneal hydrops in keratoconus – new perspectives. Am J Ophthalmol. 2014;157:921-928. http://www.ncbi.nlm.nih.gov/pubmed/24491416
Vazirani J, Basu S. Keratoconus: current perspectives. Clin Ophthalmol. 2013;7:2019-2030. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3798205/
Lu Y, Vitart V, Burdon KP, et al. Genome-wide association analyses identify multiple loci associated with central corneal thickness and keratoconus. Nat Genet. 2013;45:155-163. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3720123/
Wojcik KA, Kaminska A, Blasiak J, Szaflik J, Szaflik JP. Oxidative stress in the pathogenesis of keratoconus and Fuchs endothelial corneal dystrophy. Int J Mol Sci. 2013;14:19294-19308. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3794834/
Keating A, Pineda R 2nd, Colby K. Corneal cross linking for keratoconus. Semin Ophthalmol. 2010;25:249-255. http://www.ncbi.nlm.nih.gov/pubmed/21091008
Shoham A, Hadziahmetovic M, Dunaief JL, Mydlarski MB, Schipper HM. Oxidative stress in diseases of the human cornea. Free Radic Biol Med. 2008;45:1047-1055. http://www.ncbi.nlm.nih.gov/pubmed/18718524
Zadnik K, Barr JT, Edrington TB, et al. Corneal scarring and vision in keratoconus: a baseline report from the Collaborative Longitudinal Evaluation of Keratoconus (CLEK) Study. Cornea. 2000;19:804-12. http://www.ncbi.nlm.nih.gov/pubmed/11095054
Wang Y, Rabinowitz YS, Rotter JI, Yang H. Genetic epidemiological study of keratoconus: evidence for major gene determination. Am J Med Genet. 2000;93:403-09. http://www.ncbi.nlm.nih.gov/pubmed/10951465
Rabinowitz YS, Maumenee M, Lundergan MK, et al. Molecular genetic analysis in autosomal dominant keratoconus. Cornea. 1992;11:302-08. http://www.ncbi.nlm.nih.gov/pubmed/1358551
McDonnell PJ, Garbus J, Romeo JL, Rao NA, Schanzlin DJ. Electrosurgical keratoplasty. Clinicopathologic correlation. Arch Ophthalmol. 1988;106:235-38. http://www.ncbi.nlm.nih.gov/pubmed/3277609
Ihalainen A. Clinical and epidemiological features of keratoconus: genetic and external factors in the pathogenesis of the disease. Acta Ophthal Suppl. 1986;178:1-66. http://www.ncbi.nlm.nih.gov/pubmed/3019073
Kennedy RH, Bourne WM, Dyer JA. A 48-year clinical and epidemiologic study of keratoconus. Am J Ophthalmol. 1986;101:267-73. http://www.ncbi.nlm.nih.gov/pubmed/3513592
FROM THE INTERNET
Wayman LL. Keratoconus. UpToDate, Inc. 2015 Apr 21. Available at: http://www.uptodate.com/contents/keratoconus Accessed on: October 15, 2014.
Weissman BA, Yeung KK. Keratoconus. Emedicine Journal, April 22 2014. Available at: http://emedicine.medscape.com/article/1194693-overview Accessed on: June October 10, 2015.
Mayo Clinic for Medical Education and Research. Keratoconus. February 20, 2013. Available at: http://www.mayoclinic.org/diseases-conditions/keratoconus/basics/definition/con-20024697 Accessed On: October 10, 2015.
The information in NORD’s Rare Disease Database is for educational purposes only and is not intended to replace the advice of a physician or other qualified medical professional.
The content of the website and databases of the National Organization for Rare Disorders (NORD) is copyrighted and may not be reproduced, copied, downloaded or disseminated, in any way, for any commercial or public purpose, without prior written authorization and approval from NORD. Individuals may print one hard copy of an individual disease for personal use, provided that content is unmodified and includes NORD’s copyright.
National Organization for Rare Disorders (NORD)
55 Kenosia Ave., Danbury CT 06810 • (203)744-0100